Eisai And Biogen’s LEQEMBI IQLIK Honored By TIME As One Of The Best Medical Innovations Of 2025

Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab for Alzheimer’s disease (AD), has been named one of TIME’s “Best Inventions of 2025” in the Medical and Healthcare category. The annual TIME list highlights 300 groundbreaking innovations that are transforming lives across industries, with nominees evaluated based on originality, efficacy, ambition, and impact.

LEQEMBI IQLIK is the first and only anti-amyloid therapy designed for at-home use, allowing patients and caregivers to continue slowing disease progression beyond the initial 18-month treatment phase. Approved by the U.S. FDA in August 2025 and launched on October 6, the autoinjector delivers treatment in about 15 seconds, reducing the need for infusion center visits. This advancement is expected to ease healthcare resource demands, increase infusion capacity for new patients, and streamline Alzheimer’s treatment pathways globally.

The original LEQEMBI, recognized by TIME in 2023, remains the first approved anti-amyloid drug proven to slow cognitive and functional decline in adults with early-stage Alzheimer’s, including mild cognitive impairment (MCI) and mild dementia. Now approved in 50 countries and under review in 10 more, Eisai recently submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA for LEQEMBI IQLIK as a subcutaneous starting dose under Fast Track Status. Eisai leads global development and regulatory submissions, while Eisai and Biogen jointly handle commercialization and promotion.